Glenmark Pharmaceuticals share price
You have to be logged in to add this to Watchlist.Glenmark Pharmaceuticals is trading -1.64% lower at Rs 1,713.35 as compared to its last closing price. Glenmark Pharmaceuticals has been trading in the price range of 1,745.95 & 1,708.90. Glenmark Pharmaceuticals has given 103.93% in this year & 2.19% in the last 5 days.
There are 10 analysts who have initiated coverage on Glenmark Pharmaceuticals. There are 4 analysts who have given it a strong buy rating & 2 analysts have given it a buy rating. 1 analysts have given the stock a sell rating.
The company posted a net profit of 340.27 Crores in its last quarter.
Listed peers of Glenmark Pharmaceuticals include Alkem Laboratories (1.30%), Abbott India (-0.83%), Glenmark Pharmaceuticals (-1.64%) etc.
Glenmark Pharmaceuticals has a 46.65% promoter holding & 53.35% public holding.The Mutual Fund holding in Glenmark Pharmaceuticals was at 1.95% in 30 Jun 2024. The MF holding has decreased from the last quarter. The FII holding in Glenmark Pharmaceuticals was at 20.98% in 30 Jun 2024. The FII holding has decreased from the last quarter.
Glenmark Pharmaceuticals share price range
|
| ||||
|
| ||||
Glenmark Pharmaceuticals share Key Metrics
| Market Cap ( ₹ Cr.) | 49,141.66 | ||||||||||||||||||
|
|
Technical Trends
Long TermConsiders price movement over the last 6 months
Short TermConsiders price movement over the last 1-2 weeks
- Bearish
- Moderately Bearish
- Neutral
- Moderately Bullish
- Bullish
Insight: Trends unavailable at the moment.
Glenmark Pharmaceuticals Corporate actions
- Board Meetings
- AGM
- Dividends
- Bonus
- Split
- Rights
| Meeting Date | Purpose |
| 14-Aug-24 | Quarterly Results |
| 24-May-24 | Audited Results & Final Dividend |
| 14-Feb-24 | Quarterly Results |
| 10-Nov-23 | Quarterly Results |
| 11-Aug-23 | Quarterly Results |
| 19-May-23 | Audited Results & Final Dividend |
| 10-Feb-23 | Quarterly Results |
| 11-Nov-22 | Quarterly Results |
| 10-Aug-22 | Quarterly Results |
| 27-May-22 | Audited Results & Final Dividend |
| Meeting Date | Announcement On | Purpose |
| 09-Nov-23 | 06-Oct-23 | POM |
| 29-Sep-23 | 25-Aug-23 | AGM |
| 06-Aug-23 | 05-Jul-23 | POM |
| 16-Apr-23 | 15-Mar-23 | POM |
| 16-May-22 | 13-Apr-22 | POM |
| Announcement On | Record Date | Ex-Dividend | Dividend Value |
| 24-May-24 | - | 13-Sep-24 | 2.5 |
| 19-May-23 | - | 18-Sep-23 | 2.5 |
| 30-May-22 | - | 12-Sep-22 | 2.5 |
| 28-May-21 | - | 08-Sep-21 | 2.5 |
FAQs about Glenmark Pharmaceuticals share price
Glenmark Pharmaceuticals is trading at 1713.35 as on Tue Sep 17 2024 10:15:25. This is -1.64% lower as compared to its previous closing price of 1741.85.
The market capitalization of Glenmark Pharmaceuticals is 48348.71 Cr as on Tue Sep 17 2024 10:15:25.
The average broker rating on Glenmark Pharmaceuticals is Buy. The breakup of analyst rating is given below -
- 4 analysts have given a strong buy rating
- 2 analysts have given a buy rating
- 3 analysts have given a hold rating
- 1 analysts have given a sell rating
- 0 analysts have given a strong sell rating
The 52 wk high for Glenmark Pharmaceuticals is 1773.95 whereas the 52 wk low is 722.25
Glenmark Pharmaceuticals can be analyzed on the following key metrics -
- TTM P/E: -
- Sector P/E: 32.36
- Dividend Yield: 0.14%
- D/E ratio: -
Glenmark Pharmaceuticals reported a net profit of -1501.67 Cr in 2024.
Glenmark Pharmaceuticals Quick Links
Glenmark Pharmaceuticals Dividend Glenmark Pharmaceuticals Bonus Glenmark Pharmaceuticals News Glenmark Pharmaceuticals AGM Glenmark Pharmaceuticals Rights Glenmark Pharmaceuticals Splits Glenmark Pharmaceuticals Board Meetings Glenmark Pharmaceuticals Key Metrics Glenmark Pharmaceuticals Shareholdings Glenmark Pharmaceuticals Profit Loss Glenmark Pharmaceuticals Balance Sheet Glenmark Pharmaceuticals Cashflow Glenmark Pharmaceuticals Q1 Results Glenmark Pharmaceuticals Q2 Results Glenmark Pharmaceuticals Q3 Results Glenmark Pharmaceuticals Q4 Results
Equity Quick Links
Top GainersTop LosersIndian IndicesBSE Active StocksNSE Active Stocks